GSK - Annual Review 2006 banner
GSK - Summary financial statements banner image
  • Home
  • About us
  • Our products
  • Your health
  • Responsibility
  • In the community
  • Research & development
  • Investors
  • Media centre
  • Careers
GlaxoSmithKline logo

Summary information under US GAAP

The following is a summary of the material adjustments to profit and shareholders’ funds which would be required if US Generally Accepted Accounting Principles (US GAAP) had been applied instead of IFRS.

Summary information under US GAAP

Profit

2006
£m
2005
£m
Profit after taxation for the year under IFRS 5,498 4,816
Profit attributable to minority interests (109) (127)
Profit attributable to shareholders under IFRS 5,389 4,689
US GAAP adjustments:    
– Product rights and goodwill (1,391) (1,682)
– Depreciation and impairment of other assets (93) (40)
– Capitalised interest 4 (1)
– Investments (10) (2)
– Employee costs (197) (121)
– Derivative instruments and hedging 477 (30)
– Restructuring costs (16) 1
– Taxation 292 538
– Other (16)
Net income under US GAAP before cumulative effect of change in accounting principle 4,455 3,336
Cumulative effect of change in accounting principle 10
Net income under US GAAP    4,465 3,336
     

Earnings per share

2006 2005
Basic net income per share before cumulative effect of change in accounting principle 78.9p 58.8p
Cumulative effect of change in accounting principle per share 0.2p
Basic net income per share after cumulative effect of change in accounting principle 79.1p 58.8p
Diluted income per share before cumulative effect of change in accounting principle 78.2p 58.3p
Cumulative effect of change in accounting principle per share 0.2p
Diluted net income per share after cumulative effect of change in accounting principle 78.4p 58.3p
     

Equity shareholders’ funds

2006
£m
2005
£m
Total equity under IFRS 9,648 7,570
Minority interests (262) (259)
Shareholders’ equity under IFRS 9,386 7,311
US GAAP adjustments:    
– Product rights and goodwill       28,583 30,041
– Fixed assets  and capitalised interest   148 212
– Inventory impairment reversals (54) (30)
– Investments 500 576
– Pensions and other post-retirement benefits 35 1,249
– Restructuring costs 39 65
– Derivative instruments (44) (33)
– Dividends (676) (568)
– Deferred taxation (3,262) (4,531)
– Other (2) (10)
Shareholders’ equity under US GAAP 34,653 34,282

A summary of the material differences between IFRS and US GAAP that apply to the Group is set out in the Annual Report 2006.